Trevi Therapeutics, Inc. TRVI Effective Income Tax Rate Reconciliation Tax Credits Research
Effective Income Tax Rate Reconciliation Tax Credits Research at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch.
The official record: Trevi Therapeutics, Inc.’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s effective income tax rate reconciliation tax credits research.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s effective income tax rate reconciliation tax credits research?
- Trevi Therapeutics, Inc. (TRVI) reported effective income tax rate reconciliation tax credits research of -2.7% in Q4 2025.
- How has Trevi Therapeutics, Inc.'s effective income tax rate reconciliation tax credits research changed year-over-year?
- Trevi Therapeutics, Inc.'s effective income tax rate reconciliation tax credits research decreased by 17.4% year-over-year, from -2.3% to -2.7%.
- What does effective income tax rate reconciliation tax credits research mean?
- This metric represents the impact of research and development tax credits on the effective income tax rate reconciliation. It quantifies how R&D-related tax incentives reduce the company's theoretical tax burden compared to the statutory rate. This is a key indicator of tax efficiency for clinical-stage biopharmaceutical firms heavily invested in innovation.